Search company, investor...

Shire Pharmaceuticals Group


Asset Sale | AssetsPurchased

About Shire Pharmaceuticals Group

Shire Pharmaceuticals Group is an international specialty pharmaceutical company with a strategic focus on four therapeutic areas: central nervous system disorders, metabolic diseases, oncology and gastroenterology.

Headquarters Location

Wayne, Pennsylvania, 19080,

United States

Missing: Shire Pharmaceuticals Group's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Shire Pharmaceuticals Group's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Shire Pharmaceuticals Group

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Shire Pharmaceuticals Group is included in 1 Expert Collection, including Cancer.



1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Shire Pharmaceuticals Group Patents

Shire Pharmaceuticals Group has filed 1 patent.

The 3 most popular patent topics include:

  • Alternative medicine
  • Mood disorders
  • Psychiatric diagnosis
patents chart

Application Date

Grant Date


Related Topics



Psychiatric diagnosis, Therapy, Surgical removal procedures, Mood disorders, Alternative medicine


Application Date


Grant Date


Related Topics

Psychiatric diagnosis, Therapy, Surgical removal procedures, Mood disorders, Alternative medicine



Latest Shire Pharmaceuticals Group News

Shire plc : Rule 2.9 Announcement

Aug 3, 2018

| Source: Shire Pharmaceuticals Group NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 3 August 2018 Rule 2.9 Announcement In accordance with Rule 2.9 of the City Code on Takeovers and Mergers, the Company confirms that, as at the close of business on 2 August 2018, being the last business day prior to the date of this announcement, it had 921,770,124 ordinary shares of 5 pence each in issue and admitted to trading on the main market of the London Stock Exchange. Shire holds 7,357,283 ordinary shares in treasury. Accordingly, the total number of voting rights in Shire is 914,412,841. Shire has an American Depositary Share ("ADS") programme for which Citibank, N.A. acts as depositary. One ADS represents three ordinary shares of 5 pence each, with ISIN US82481R1068. The ADSs trade on the NASDAQ Global Select Market. Enquiries:

Shire Pharmaceuticals Group Frequently Asked Questions (FAQ)

  • Where is Shire Pharmaceuticals Group's headquarters?

    Shire Pharmaceuticals Group's headquarters is located at Wayne.

  • What is Shire Pharmaceuticals Group's latest funding round?

    Shire Pharmaceuticals Group's latest funding round is Asset Sale.

  • Who are the investors of Shire Pharmaceuticals Group?

    Investors of Shire Pharmaceuticals Group include Supernus Pharmaceuticals, Richwood Pharmaceutical, SV Health Investors and EW Healthcare Partners.

  • Who are Shire Pharmaceuticals Group's competitors?

    Competitors of Shire Pharmaceuticals Group include Unither Pharmaceuticals, Arena Pharmaceuticals, Neurelis, United Biomedical, Adastra Pharmaceuticals, Aegerion Pharmaceuticals, Solasia Pharma, aTyr Pharma, Meritage Pharma, Azevan Pharmaceuticals and 24 more.

Compare Shire Pharmaceuticals Group to Competitors

Neurelis Logo

Neurelis is a specialty pharmaceutical company that devleops and commercializes product candidates for epilepsy and the broader central nervous system (CNS) market.


The company is engaged in developing and commercializing drugs for the hospital-based treatment of central nervous system (CNS) disorders and thrombotic/cardiovascular diseases, indications for which there is a substantial unmet medical need.

Ikano Therapeutics

Ikano Therapeutics is a specialty pharmaceutical company focused on developing nasally delivered pharmaceutical products with a particular focus on drugs treating pain and disorders related to the central nervous system.


Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.

Neurocure Logo

Neurocure is a specialty pharma company working on psychiatric and central nervous system diseases.

Richwood Pharmaceutical

Richwood develops drugs for disorders of the central nervous system, particularly hyperactivity in children.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.